About Katzung Pharmaceuticals
Katzung Pharmaceuticals is a Healthcare company. Pharmaceutical production and medicine distribution in India with a focus on quality. The company has 30 employees. Its Indian entity Katzung Pharmaceuticals Private Limited reported revenue of ₹6.17 Cr. Katzung Pharmaceuticals offers products and services including Teneligliptin Tablets and Rosuvastatin Tablets. Its focus areas include Pharmaceuticals, Drug Manufacturing, Generic Medicines and Distribution.
Company details
Katzung Pharmaceuticals is noted for its dedication to quality in the pharmaceutical sector, where quality is seen as the outcome of intelligent efforts and is tied to organizational growth. Medicines distributed by the company are subjected to thorough scrutiny, including inspections by national managers on aspects like manufacturing, packaging, and durability. The company operates from offices in Telangana and Bangalore, India, offering products such as Teneligliptin and Rosuvastatin tablets, ensuring high standards in every detail.
- Employees 30
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website katzungpharma.com
- Legal Name Katzung Pharmaceuticals Pvt Ltd
- Date of Incorporation 27 Jun, 2017
- Jurisdiction Hyderabad, Telangana, India
- Indian entity revenue₹6.17 Cr
FY 2024 · +9% YoY
- Indian entity net profit₹52.1 Lakh
FY 2024 · 8% margin
- Indian entity EBITDA₹84.2 Lakh
FY 2024 · 14% margin
- Employee Count30
Associated legal entities of Katzung Pharmaceuticals
Katzung Pharmaceuticals operates through Katzung Pharmaceuticals Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Katzung Pharmaceuticals Private Limited CIN U74999TG2017PTC117959 | Active | 27 Jun 2017 | Hyderabad, Telangana | ₹6.2 Cr | 30 | 4 | View details |
Products & Services of Katzung Pharmaceuticals
Katzung Pharmaceuticals offers a comprehensive portfolio of products and services, including Teneligliptin Tablets and Rosuvastatin Tablets.
These tablets are provided for diabetes management, with emphasis on quality scrutiny in production and packaging.
These tablets are offered for cholesterol control, undergoing extensive checks on manufacturing and distribution processes.
Board of directors of Katzung Pharmaceuticals Private Limited (Katzung Pharmaceuticals)
Katzung Pharmaceuticals Private Limited is the primary company behind Katzung Pharmaceuticals. The board of Katzung Pharmaceuticals Private Limited currently have 4 directors; the longest-serving is Mahesh Babu Jambuladinne, appointed in 2017. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Mahesh Babu Jambuladinne DIN 07857647 | Director | 27 Jun 2017 | 9 yrs 4 mo | Katzung Pharmaceuticals Private Limited |
| Amar Vennapusa DIN 07595055 | Director | 27 Jun 2017 | 9 yrs 4 mo | Katzung Pharmaceuticals Private Limited |
| Syam Sundar Mukharjee Madivada DIN 07183706 | Director | 27 Jun 2017 | 9 yrs 4 mo | Katzung Pharmaceuticals Private Limited |
| Kranthi Kumar Chintala DIN 07872877 | Additional Director | 08 Jul 2017 | 9 yrs 4 mo | Katzung Pharmaceuticals Private Limited |
Financials of Katzung Pharmaceuticals
Figures of Katzung Pharmaceuticals Private Limited, the primary company behind Katzung Pharmaceuticals, for FY 2024. Revenue was ₹6.17 Cr (+9% year on year). Net profit was ₹52.1 Lakh (8% margin). EBITDA was ₹84.2 Lakh (14% margin). Revenue has grown at a compounded annual rate of +21% over three years and +30% over five years.
- ₹6.17 CrRevenue · FY 2024 · +9% YoY
- ₹52.1 LakhNet profit · 8% margin
- ₹84.2 LakhEBITDA · 14% margin
- ₹5 LakhPaid-up capital
- 30Employees (provident fund records)
- +21%Revenue CAGR, 3 years
- +30%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Katzung Pharmaceuticals Private Limited are on its company page.
Detailed financial statements for Katzung Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Katzung Pharmaceuticals
Katzung Pharmaceuticals has 30 employees.
The primary company behind Katzung Pharmaceuticals, Katzung Pharmaceuticals Private Limited, reported revenue of ₹6.17 Cr for FY 2024, up 9% year on year.
Katzung Pharmaceuticals is noted for its dedication to quality in the pharmaceutical sector, where quality is seen as the outcome of intelligent efforts and is tied to organizational growth. Medicines distributed by the company are subjected to thorough scrutiny, including inspections by national managers on aspects like manufacturing, packaging, and durability. The company operates from offices in Telangana and Bangalore, India, offering products such as Teneligliptin and Rosuvastatin tablets, ensuring high standards in every detail.
Katzung Pharmaceuticals offers Teneligliptin Tablets and Rosuvastatin Tablets.
Katzung Pharmaceuticals operates through Katzung Pharmaceuticals Private Limited.
The legal entities of Katzung Pharmaceuticals currently have 4 directors, including Kranthi Kumar Chintala, Mahesh Babu Jambuladinne, Amar Vennapusa and others.